3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Breast
3
Tumor-Agnostic
2
Thoracic
2
Genitourinary
2
Sarcoma
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
32
Everolimus
19
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
12
Temozolomide
12
Nivolumab
11
Capecitabine
10
pembrolizumab
9
lanreotide
9
cabozantinib
8
Positron Emission Tomography Computed Tomography
8
177Lu-octreotide, DOTA(0)-Tyr(3)-
8
Ga(III)-DOTATOC
7
3-Iodobenzylguanidine
7
Somatostatin
6
Octreotide
6
Lutetium-177
6
Carboplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
surufatinib
5
lenvatinib
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
pasireotide
4
copper dotatate CU-64
4
avelumab
4
Single Photon Emission Computed Tomography Computed Tomography
4
Positron-Emission Tomography
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Poly(ADP-ribose) Polymerase Inhibitors
×
NET
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled